71 related articles for article (PubMed ID: 1363759)
1. [Expression of proliferating cell nuclear antigen (PCNA) and its correlation with Ki-67, TfR, ET, PgR, pTNM in carcinoma of the breast].
Rizzo A; Crisafulli C; Maiorca A; Tuccari G
Pathologica; 1992; 84(1094):65-9. PubMed ID: 1363759
[No Abstract] [Full Text] [Related]
2. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
[TBL] [Abstract][Full Text] [Related]
3. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
Narita T; Funahashi H; Satoh Y; Takagi H
Jpn J Clin Oncol; 1993 Feb; 23(1):20-5. PubMed ID: 8096256
[TBL] [Abstract][Full Text] [Related]
4. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
Markiewski M; Domagała W
Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
[TBL] [Abstract][Full Text] [Related]
7. Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells.
Qiao L; Pizzolo JG; Melamed MR
Biochem Biophys Res Commun; 1994 Jun; 201(2):581-8. PubMed ID: 7911660
[TBL] [Abstract][Full Text] [Related]
8. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
Yu CC; Dublin EA; Camplejohn RS; Levison DA
Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
[TBL] [Abstract][Full Text] [Related]
9. Proliferative activity is a significant prognostic factor in male breast carcinoma.
Pich A; Margaria E; Chiusa L
Am J Pathol; 1994 Aug; 145(2):481-9. PubMed ID: 7519830
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in Hungarian breast cancer patients.
Nádasi E; Anga B; Sándor J; Megyesi J; Kelemen D; Mottolese M; Natali PG; Hegedus G; Arany I; Ember I
Anticancer Res; 2007; 27(1A):279-82. PubMed ID: 17352244
[TBL] [Abstract][Full Text] [Related]
11. Expression of proliferating cell nuclear antigen in invasive ductal carcinoma of the breast.
Horiguchi J; Iino Y; Takei H; Morishita Y; Nakajima T
Jpn J Clin Oncol; 1994 Apr; 24(2):79-84. PubMed ID: 7908995
[TBL] [Abstract][Full Text] [Related]
12. PCNA/cyclin expression in transitional cell carcinomas of the human bladder: its correlation with Ki-67 and epidermal growth factor receptor immunostainings.
Serio G
Pathologica; 1994 Apr; 86(2):161-6. PubMed ID: 7936759
[TBL] [Abstract][Full Text] [Related]
13. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical detection of cell proliferation-related antigens in cytologic smears of human malignant neoplasms using PC10, reactive with proliferating cell nuclear antigen, and Ki-67. A comparative study.
Pelosi G; Bresaola E; Manfrin E; Rodella S; Schiavon I; Iannucci A
Arch Pathol Lab Med; 1994 May; 118(5):510-6. PubMed ID: 7910728
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the expression of estrogen and progesteron receptors, and of PCNA and Ki67 proliferation antigens, in uterine myomata cells in relation to the phase of the menstrual cycle.
Zasławski R; Surowiak P; Dziegiel P; Pretnik L; Zabel M
Med Sci Monit; 2001; 7(5):908-13. PubMed ID: 11535933
[TBL] [Abstract][Full Text] [Related]
16. [Expression of estrogen and progesterone receptors and HER-2 by breast cancer cells].
Zaĭrat'iants OV; Kolobov SV; Akopian IG; Opalenov KV; Barsanova TG
Arkh Patol; 2004; 66(5):9-12. PubMed ID: 15575377
[TBL] [Abstract][Full Text] [Related]
17. Use of proliferative markers Ki-67 (MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis.
Cheville JC; Terrell RB; Cohen MB
Mod Pathol; 1994 Sep; 7(7):794-800. PubMed ID: 7824516
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
19. Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody.
Marchetti E; Querzoli P; Marzola A; Bagni A; Ferretti S; Fabris G; Nenci I
Mod Pathol; 1990 Jan; 3(1):31-5. PubMed ID: 2308919
[TBL] [Abstract][Full Text] [Related]
20. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
